2026 NPPES data Gynecologic Oncology Physician NPI 1487659876 MD
Verify on CMS →

MARK REEDY, MD

Gynecologic Oncology Physician in LUBBOCK, Texas. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
577
Medicare Part D claims · 84 beneficiaries · Gynecologic Oncology Physician avg: 188
Generic prescribing
95%
generic claims · 5% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
100/100
▲ 17 pts above national avg 83.1 · [object Object]

What the federal data shows

MARK REEDY, MD reported a CMS MIPS final score of 100/100 — above the 83.1 national average — and filed 577 Medicare Part D claims in 2023.

100/100
MIPS score · +17 vs avg
577
Part D claims, 2023
95%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

MARK REEDY, MD's MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

100 Top 7% higher than 93% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). Below this entry. 80–90: 129,887 scored providers (27%). Below this entry. 90–100: 189,403 scored providers (40%). This entry sits in this band. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

MARK REEDY, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about MARK REEDY, MD?

High performer (top quartile)

NPI registry status

Active

Issued 06/14/2005

NPI 1487659876

Primary specialty

Gynecologic Oncology Physician

Niche

1,360 US NPIs in this specialty

Medicare Part D claims

577 207% vs specialty avg

2023 prescription claims

Specialty avg: 188

MIPS final score

100/100 16.900000000000006% pts

Exceptional band

vs 83.1 national avg

Specialty distribution in Texas

How Gynecologic Oncology Physician compares to other specialties among Texas providers

Texas providers

Gynecologic Oncology Physician share within Texas

1. Gynecologic Oncology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Gynecologic Oncology Physician share within Texas

Medicare quality performance — MIPS

MARK REEDY, MD's 2023 MIPS final score plotted against the Gynecologic Oncology Physician national average

High performer (top quartile)
MIPS Final Score
100/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Gynecologic Oncology Physician) — 100/100 vs national avg 83.1

0%100%National avg83%99%
MIPS final score (Gynecologic Oncology Physician) — 100/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

MARK REEDY, MD appears in the CMS NPPES registry as a Gynecologic Oncology Physician provider holding MD credentials at 602 INDIANA AVE, LUBBOCK, TX, 79415, with a listed phone of (806) 775-8600. NPI 1487659876 was issued on 06/14/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what REEDY most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 577 prescription claims written by this provider, covering 84 Medicare beneficiaries and totaling roughly $142K in drug spend, split 5% brand-name and 95% generic by claim count, with an opioid prescribing rate of 11.1%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 100/100 for the 2023 performance year (Quality 91.1945), compared with the national average of 83.1.

Gynecologic Oncology Physician is a narrow specialty nationwide, with 1,360 enrolled providers across 49 states and an average of 188 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

602 INDIANA AVE
LUBBOCK, TX 79415

Provider Details

NPI 1487659876
Specialty Gynecologic Oncology Physician
Credentials MD
Gender Male
NPI Issued 06/14/2005

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

100
Final Score
Avg: 83.1
91.1945
Quality
100
Promoting Interoperability

Reporting: Alternative Payment Model

Hospital and facility affiliations

Facilities where MARK REEDY, MD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER LUBBOCK
LUBBOCK, TX

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

License & disciplinary context — Texas TMB 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~77K Texas medical licensees in 2023 — they are NOT specific to MARK REEDY, MD. To verify MARK REEDY, MD's current license status, search the TMB public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

344
Total board actions, Texas 2023
Across 334 cases
4.47
Actions per 1,000 licensees
Texas statewide rate
probation
Most common action type
94 cases

TMB publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Texas disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Generic-heavy

MARK REEDY, MD — brand share 5.0%
Specialty average (est.)

5% brand-name claims vs 95% generic, on 577 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

577
Total Claims
$142K
Total Drug Cost
84
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
923
Total Day Supply
25,198
Brand vs Generic
5% brand / 95% generic
Brand Drug Cost
$125K
Generic Drug Cost
$16K
Opioid Claims
64 (11.1% rate)
Antibiotic Claims
33

Patient Demographics

Average Patient Age
68.9 years
Avg HCC Risk Score
1.58
Age Distribution
<65: 20, 65-74: 41, 75-84: N/A, 85+: N/A

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What MARK REEDY, MD prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Letrozole
119
Alendronate Sodium
96
Hydrocodone-Acetaminophen
Hydrocodone/Acetaminophen
43
Pantoprazole Sodium
27
Metformin Hcl
20
Ondansetron Hcl
16
Trazodone Hcl
16
Fentanyl
15
Lidocaine-Prilocaine
Lidocaine/Prilocaine
15
Medroxyprogesterone Acetate
15

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Gynecologic Oncology Physician Overview

How MARK REEDY, MD fits within the Gynecologic Oncology Physician landscape nationally.

1,360
Gynecologic Oncology Physician Providers in US
49
States with Gynecologic Oncology Physician
188
Avg Claims per Provider

MARK REEDY, MD's 577 claims are above the specialty average of 188.

Nearby Gynecologic Oncology Physician Providers in Texas

Other clinicians with the same primary specialty enrolled in Texas, drawn from the same CMS NPPES roster as REEDY.

Compare Gynecologic Oncology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is MARK REEDY, MD's specialty?
MARK REEDY, MD specializes in Gynecologic Oncology Physician and practices in LUBBOCK, Texas. Credentials: MD.
How much does MARK REEDY, MD prescribe under Medicare Part D?
In 2023, MARK REEDY, MD wrote 577 Medicare Part D claims totaling $142K in drug costs for 84 beneficiaries.
What is MARK REEDY, MD's Medicare quality score?
MARK REEDY, MD has a CMS MIPS Final Score of 100/100 (Quality: 91.1945). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is MARK REEDY, MD located?
MARK REEDY, MD is located at 602 INDIANA AVE, LUBBOCK, TX, 79415. Phone: (806) 775-8600.
What is MARK REEDY, MD's NPI number?
MARK REEDY, MD's National Provider Identifier (NPI) is 1487659876, issued on 06/14/2005.
Does MARK REEDY, MD prescribe more brand-name or generic drugs?
MARK REEDY, MD's prescribing is 5% brand-name and 95% generic drugs by claim count, with $125K in brand drug costs.
Does MARK REEDY, MD prescribe opioids?
Yes, MARK REEDY, MD had 64 opioid claims in 2023 with an opioid prescribing rate of 11.1%.
How many Gynecologic Oncology Physician providers are there in the US?
There are 1,360 Gynecologic Oncology Physician providers across 49 states in the US. The average Gynecologic Oncology Physician provider writes 188 Medicare Part D claims per year.
What drugs does MARK REEDY, MD prescribe most often?
Based on 2023 Medicare Part D data, MARK REEDY, MD's most frequently prescribed drugs include Letrozole, Alendronate Sodium, Hydrocodone-Acetaminophen. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does MARK REEDY, MD accept Medicare?
MARK REEDY, MD appears in CMS Medicare data with 577 Part D claims and 84 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify MARK REEDY, MD's credentials?
MARK REEDY, MD's NPI is 1487659876 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology